Vascular Solutions to Participate in Bank of America Merrill Lynch 2013 Health Care Conference

        Print
| Source: Vascular Solutions, Inc.

MINNEAPOLIS, May 8, 2013 (GLOBE NEWSWIRE) -- Vascular Solutions, Inc. (Nasdaq:VASC) today announced that the Company is scheduled to participate in the Bank of America Merrill Lynch 2013 Health Care Conference being held at The Encore at Wynn in Las Vegas.

James Hennen, Chief Financial Officer of Vascular Solutions, will present on Wednesday, May 15th at 5:00pm (PDT). To hear the live audio webcast of the panel discussion, go to the investor relations page of the Company's web site http://www.vasc.com and click on the "Investor Conferences" icon a few minutes prior to start time to download any necessary software.

About Vascular Solutions

Vascular Solutions, Inc. is an innovative medical device company that focuses on developing unique clinical solutions for coronary and peripheral vascular procedures. The company's product line consists of over 75 products in three categories: catheter products, hemostat products and vein products. Vascular Solutions delivers its products to interventional cardiologists, interventional radiologists, electrophysiologists, and vein specialists through its direct U.S. sales force and international independent distributor network.

The information in this press release contains forward-looking statements, including statements regarding the international availability of the Venture catheter and expectations about the product's sales, that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K for the year ended December 31, 2012 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, lack of sustained profitability, exposure to intellectual property claims, significant variability in quarterly results, exposure to possible product liability claims, the development of new products by others, doing business in international markets, the availability of third party reimbursement, and actions by the FDA.

For further information, connect to www.vasc.com.
 

James Hennen, CFO
Phil Nalbone, VP
Vascular Solutions, Inc.
(763) 656-4300